ALK Tyrosine Kinase Inhibitors in ALK-rearranged Advanced Squamous Cell Carcinoma

This study was to explore the efficacy of ALK-TKI in lung squamous cell carcinoma. Approximately 5% of lung adenocarcinomas have oncogenic fusions of EML-4 and ALK a mutation associated with tumorigenesis and migration.

Trial Details

NCT ID
NCT05014464
Phase
PHASE2
Sponsor
Hunan Province Tumor Hospital
Status
RECRUITING
Cancer Type
Adenocarcinoma Lung Cancer
Interventions
  • Crizotinib
Locations (sample)
  • Changsha, Hunan, China|28.19874,112.97087

Key Eligibility Criteria

  • Understand the requirements and contents of the clinical trial, and provide a signed and dated informed consent form.
  • Age ≥ 18 years.
  • Histopathology or cytology confirmed and recorded local progression or metastatic Advanced Squamous Cell Carcinoma without systemic treatment.
  • ALK fusion positive evaluated by IHC (ventana), NGS or FISH.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Adenocarcinoma Lung Cancer Trials on Trialify →